documents
Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API
6 rows where docket_id = "FDA-2024-N-5381" sorted by posted_date descending
This data as json, CSV (advanced)
Suggested facets: subtype, posted_date, posted_month, posted_date (date), comment_start_date (date), last_modified (date)
document_type 2
agency_id 1
- FDA 6
| id | agency_id | docket_id | title | document_type | subtype | posted_date ▲ | posted_year | posted_month | comment_start_date | comment_end_date | last_modified | fr_doc_num | open_for_comment | withdrawn | object_id |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| FDA-2024-N-5381-0005 | FDA | None FDA-2024-N-5381 | Reference 18 Buprenorphine dosing for the treatment of opioid use disorder | Supporting & Related Material | Background Material | 2025-01-06T05:00:00Z | 2025 | 1 | 2025-01-06T19:19:09Z | 0 | 0 | 09000064868a01ee | |||
| FDA-2024-N-5381-0002 | FDA | None FDA-2024-N-5381 | Reference 15 Evidence on Buprenorphine Dose Limits A Review | Supporting & Related Material | Background Material | 2025-01-06T05:00:00Z | 2025 | 1 | 2025-01-06T19:18:56Z | 0 | 0 | 09000064868a017e | |||
| FDA-2024-N-5381-0004 | FDA | None FDA-2024-N-5381 | Reference 17 The effect of serum from women with antiphospholipid | Supporting & Related Material | Background Material | 2025-01-06T05:00:00Z | 2025 | 1 | 2025-01-06T19:19:03Z | 0 | 0 | 09000064868a0180 | |||
| FDA-2024-N-5381-0003 | FDA | None FDA-2024-N-5381 | Reference 16 Thematic Analysis of State Medicaid Buprenorphine | Supporting & Related Material | Background Material | 2025-01-06T05:00:00Z | 2025 | 1 | 2025-01-06T19:18:59Z | 0 | 0 | 09000064868a017f | |||
| FDA-2024-N-5381-0006 | FDA | None FDA-2024-N-5381 | Reference 22 Preliminary buprenorphine sublingual tablet pharmacokinetic | Supporting & Related Material | Background Material | 2025-01-06T05:00:00Z | 2025 | 1 | 2025-01-06T19:19:13Z | 0 | 0 | 09000064868a01ef | |||
| FDA-2024-N-5381-0001 | FDA | None FDA-2024-N-5381 | Modifications to Labeling of Buprenorphine-Containing Transmucosal Products for the Treatment of Opioid Dependence | Notice | Announcement | 2024-12-27T05:00:00Z | 2024 | 12 | 2024-12-27T05:00:00Z | 2024-12-27T16:47:11Z | 2024-30776 | 0 | 0 | 090000648689153c |
Advanced export
JSON shape: default, array, newline-delimited, object
CREATE TABLE documents (
id TEXT PRIMARY KEY,
agency_id TEXT,
docket_id TEXT REFERENCES dockets(id),
title TEXT,
document_type TEXT,
subtype TEXT,
posted_date TEXT,
posted_year INTEGER,
posted_month INTEGER,
comment_start_date TEXT,
comment_end_date TEXT,
last_modified TEXT,
fr_doc_num TEXT,
open_for_comment INTEGER,
withdrawn INTEGER,
object_id TEXT
);
CREATE INDEX idx_docs_agency ON documents(agency_id);
CREATE INDEX idx_docs_docket ON documents(docket_id);
CREATE INDEX idx_docs_date ON documents(posted_date);
CREATE INDEX idx_docs_year ON documents(posted_year);
CREATE INDEX idx_docs_type ON documents(document_type);
CREATE INDEX idx_docs_frnum ON documents(fr_doc_num);
CREATE INDEX idx_docs_comment_end ON documents(comment_end_date) WHERE comment_end_date IS NOT NULL AND withdrawn = 0;